NeurAxis (NRXS) Projected to Release Quarterly Earnings on Tuesday

by · The Markets Daily

NeurAxis (NASDAQ:NRXS – Get Free Report) is projected to post its results before the market opens on Tuesday, August 11th. Analysts expect NeurAxis to announce earnings of ($0.32) per share and revenue of $2.00 million for the quarter.

NeurAxis Trading Up 4.4%

NRXS traded up $0.29 during trading on Tuesday, hitting $6.88. The stock had a trading volume of 99,150 shares, compared to its average volume of 137,543. The firm has a market cap of $85.84 million, a PE ratio of -3.74 and a beta of 1.43. NeurAxis has a 12 month low of $2.20 and a 12 month high of $9.33. The company has a 50 day simple moving average of $6.94 and a 200-day simple moving average of $6.57.

Institutional Trading of NeurAxis

Several hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC increased its position in NeurAxis by 39.6% during the third quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock worth $110,000 after acquiring an additional 10,103 shares during the period. Manatuck Hill Partners LLC acquired a new stake in NeurAxis in the 2nd quarter worth $122,000. State Street Corp acquired a new stake in NeurAxis in the 4th quarter worth $139,000. Geode Capital Management LLC increased its holdings in shares of NeurAxis by 48.8% during the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock worth $343,000 after purchasing an additional 24,817 shares during the period. Finally, Rosalind Advisors Inc. bought a new position in shares of NeurAxis during the 4th quarter worth about $1,299,000. Institutional investors own 11.77% of the company’s stock.

NeurAxis Company Profile

(Get Free Report)

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.

Featured Stories